Full Text AI-95-012 HEPATITIS C COOPERATIVE RESEARCH CENTERS NIH GUIDE, Volume 24, Number 8, March 3, 1995 RFA: AI-95-012 P.T. 34 Keywords: Infectious Diseases/Agents Viral Studies (Virology) Pathogenesis Biomedical Research, Multidiscipl National Institute of Allergy and Infectious Diseases Letter of Intent Receipt Date: April 7, 1995 Application Receipt Date: July 18, 1995 PURPOSE The Enteric Diseases Branch of the Division of Microbiology and Infectious Diseases (DMID) of the National Institute of Allergy and Infectious Diseases (NIAID) invites applications for the establishment of high-quality Hepatitis C Cooperative Research Centers (HC CRCs). The purpose of this Request for Applications (RFA) is to stimulate multidisciplinary, multi-project, collaborative research on hepatitis C virus (HCV). Such clinical and basic research will further the understanding of early and mid, rather than late (liver failure or liver cancer), stages and manifestations of hepatitis C infection, disease, and recovery. The HC CRCs will build on new findings to develop vaccine and therapy strategies. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Hepatitis C Cooperative Research Centers (HC CRCs), is related to the priority area of immunization and infectious diseases. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS Research grant applications may be submitted by domestic non-profit and for-profit organizations, public and private institutions, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal government. Foreign organizations are not eligible to apply but may be part of a collaborative arrangement as described under STUDY POPULATIONS. Racial/ethnic minority individuals, women, and persons with disabilities are encouraged to apply as Principal Investigators. MECHANISM OF SUPPORT The administrative and funding mechanism to be used to undertake this program will be the Multi-component Cooperative Agreement (U19), an "assistance" mechanism, rather than an "acquisition" mechanism. The U19 must have a minimum of three inter-related research projects around a common theme as well as collaborative efforts and interactions among component investigator-initiated projects and their investigators to achieve a common goal. Further information can be found in NIAID's "Application Guidelines for Multiproject Research Awards, November 1994," which are available from the individuals listed under INQUIRIES. The Multi-component Cooperative Agreement differs from the Program Project in that the U19 anticipates substantial NIH scientific and/or programmatic involvement with the awardee during performance of the activity. Under the cooperative agreement, the NIH's purpose is to support and/or stimulate the recipient's activity by involvement in and otherwise working jointly with the award recipient in a partner role. However, NIH is not to assume direction, prime responsibility, or a dominant role in the activity. Details of the responsibilities, relationships, and governance of the study funded under agreement(s) are discussed later in this document under the section Terms and Conditions of Award. HC CRCs may involve collaboration among investigators at several institutions. These consortium arrangements should follow the NIH "Guidelines for Establishing and Operating Consortium Grants, January 1989." These are available from the individuals listed under INQUIRIES. The total requested period for applications submitted in response to this RFA may not exceed five years. At present, the NIAID is administratively limiting the duration of U19 agreements to four years; this administrative limitation may change in the future. At this time, the NIAID has not determined whether and how this solicitation will be continued beyond the present RFA. The earliest anticipated award date is May 1, 1996. FUNDS AVAILABLE The estimated total funds (direct and indirect costs) available for the first year of support for awards under this RFA will be $1.5 million. In Fiscal Year 1996, the NIAID plans to fund two or three HC CRCs. The final number of awards to be made is dependent upon the availability of funds. The initial year's total costs, including direct and indirect costs, should not exceed $750,000 for each award. The usual PHS policies governing grants administration and management will apply. This level of support is dependent on the receipt of a sufficient number of applications of high scientific merit. Although this program is provided for in the financial plans of the NIAID, awards pursuant to this RFA are contingent upon the availability of funds for this purpose. Funding beyond the first and subsequent years of the agreement upon satisfactory progress during the preceding years and availability of funds. RESEARCH OBJECTIVES Background Hepatitis due to hepatitis C virus (HCV) is classified as an emerging infectious disease (IOM Report, 1992). Just six years ago, investigators identified HCV as an important etiological agent of non-A, non-B hepatitis and chronic liver disease through cloning and sequencing efforts. HCV infects close to 200,000 individuals each year in the U.S., affecting Hispanics and Afro-Americans disproportionately. The modes of transmission remain unidentified for an alarming 43 percent of cases. Recovery from infection is rare and at least 70 percent and quite possibly 90 percent of those infected become chronic carriers. Thus, 140,000 - 180,000 U.S. citizens become new chronic carriers each year. Even when the initial infection is asymptomatic, as it is in a high percentage of people, severe chronic liver disease with its concomitant high morbidity and mortality occurs. The CDC estimates that one to two percent of the people in the U.S., i.e., 2.5-5.0 million individuals, are chronically infected with HCV. The same one to two percent carrier rate is true around the world with the exception of a few high endemicity areas such as some inner city areas in the U.S., Egypt, the Sudan, and isolated villages in Asia. In the U.S. the total cost for HCV infection and chronic sequelae is estimated at $1.5 billion per year. Since identification of HCV considerable progress has been made. Molecular biological techniques have enabled investigators to: (1) clone and sequence many genotypes; (2) map the HCV genome and identify some of its functions; and (3) analyze structural and nonstructural proteins and the processes by which they are made. New diagnostics have been instrumental in: (1) verifying the agent causing liver disease in symptomatic patients as well as identifying asymptomatic patients; (2) preventing transmission in transfusion, transplantation and hemodialysis patients; and (3) identifying cofactors for infection and chronic disease. There have been efforts to define modes of transmission as well as affected and at risk population groups. Studies of (immuno)pathogenesis and viral replication are beginning. Despite these advances, infection and disease caused by HCV remain enigmatic, and prevention and treatment problematic. Mechanisms of liver disease and the host's role in viral persistence are largely unexplored. Significant gaps exist in the knowledge base regarding HCV's natural history and progression of disease. An obstacle to vaccine development stems from the inadequate immune response to natural infection -- viral clearance is exceedingly rare even though neutralizing antibodies have recently been detected. The large number of HCV genotypes and their high rate of mutation as well as the existence of genetic variants, i.e., "quasispecies," pose obstacles both to prevention and treatment. Alpha interferon, the only available therapy, is less than adequate and has associated toxicity. Additionally, sample sizes in human studies have often been inadequate to draw statistically significant conclusions. HCV indeed poses tough challenges for scientists and clinicians. Prevention of infection, e.g., through vaccination, and cure or amelioration of disease have the greatest promise for those at risk and affected respectively. For diseases like hepatitis B they have been shown to be highly cost-effective. Thus in this RFA, the NIAID is interested in research focused on acute and chronic disease rather than on liver failure or cancer. Objectives and Scope This RFA seeks to support state-of-the-art, innovative research on hepatitis C virus. Using integrated approaches from multiple disciplines, the HC CRCs will serve as foci for generating the knowledge needed to further understanding of HCV infection, recovery, and pathogenesis. And building on this knowledge, to devise original preventive and therapeutic interventions. The NIAID expects clinical issues and needs to be the driving forces for research performed by the HC CRCs. Relevant topics for research may include but are not limited to: o identify host responses to infection, e.g., correlates of immunity associated with prevention of infection and disease as well as recovery from acute and chronic infection; o explore host mechanisms involved in fostering and maintaining viral persistence; o identify mechanisms of pathogenesis which lead to and exacerbate liver disease; o develop small animal model and in vitro systems which are relevant for HCV vaccine, antiviral, and pathogenesis research; o develop infectious cDNA clones and utilize them in ways directly relevant to disease research; and o assess the impact of viral heterogeneity, e.g., genotypes and "quasispecies", on disease initiation and progression, the development of protective immunity, treatment outcome, etc.; o utilize findings to bridge the gaps between basic, applied, and clinical research by developing and evaluating intervention strategies, e.g., broaden or enhance protective immunity, subvert avoidance mechanisms. SPECIAL REQUIREMENTS Relevant Disciplines To foster multidisciplinary research, each HC CRC should include approaches from at least four disciplines such as virology, immunology, pathogenesis, the liver (cells, tissue, and organ) and changes (biology, biochemistry, etc.) in response to infection, clinical infection and disease, model system development, and applied research. HC CRC Collaborative Studies During the award period collaborative studies among HC CRCs may enhance research progress and increase the significance of HC CRC contributions. Examples include, but are not limited to, rapid accrual of patients or augmented access to samples. Hence, applicants should be willing to share samples as well as to participate in multicenter activities and common protocols. These will be encouraged and stimulated by the Scientific Coordinator through discussions with the Program Directors and at meetings and workshops scheduled as part of these awards. Steering Committee Meetings and Workshops To coordinate activities, facilitate interchanges, and develop collaborative opportunities, HC CRC Program Directors and the NIAID Scientific Coordinator will meet twice a year as a Steering committee. To enhance information exchange, Project Leaders will be expected to attend workshops in Years 1 and 3 of the award period. Clinical Capability To move forward with basic and clinical approaches, HC CRCs must have access to, and clinical experience with, well-characterized and diverse patient samples and populations representing different disease stages. The value of research and studies performed will be directly related to the care exercised in selection and characterization of cases and controls. Programs should include participation of human subjects to address research questions. NIAID encourages: (1) collaborative arrangements with ongoing studies or clinical care capable of providing patient populations, specimens and information; (2) applicants from institutions that have a General Clinical Research Centers (GCRC) funded by the NIH National Center for Research Resources to identify the GCRC as a resource for conducting the proposed research. In both cases letters of collaboration or agreement from the study's principal investigator and/or GCRC program director should be included in the application material. Access to and experience with patient populations also will be helpful should progress warrant studies with promising new vaccine and therapy candidates. In describing the clinical and laboratory facilities, the applicant should include specific information on present patient load, projections for patient involvement in future clinical investigations, history of recruitment and study of subjects, and disease category and prevalence as well as the availability of appropriate biohazard facilities and safety procedures. Budget and Related Issues Applications should budget appropriate funds to allow the Program Director of each HC CRC (also known as the HC CRC Director) to attend meetings in Bethesda, MD with the NIAID Scientific Coordinator twice each year and for all HC CRC Project Leaders to attend HC CRC workshops twice during the program period. Applicants should be aware that no additional travel monies will be awarded. Funds for travel to HC CRC meetings must be included in applicant's budget. (See below: SPECIAL REQUIREMENTS, Terms and Conditions of Award, 3. Collaborative Responsibilities.). Optional Developmental Fund for Pilot Studies Applicants may include a request for a Developmental Fund of up to $60,000 in direct costs to provide support for pilot projects. Such pilot projects might develop methods or resources capable of enhancing basic and clinical research progress, follow-up on new observations and hypotheses, or perform short term high risk - high benefit research. They should fit within the relevant disciplines listed above. It is envisioned that availability of funds for pilot studies will increase flexibility and responsiveness to important new scientific observations and medical reports and encourage the development of research investigators interested in hepatitis C. Pilot studies need not be restricted to the awardee institution. IT IS EMPHASIZED THAT PILOT STUDIES AWARDED FROM THE DEVELOPMENTAL FUND ARE DISTINCT FROM INDIVIDUAL HC CRC RESEARCH PROJECTS. Direct costs may not exceed $20,000 for any single pilot study and supplies and equipment expenditures may not exceed $7,000 annually per study. The duration of support for each study typically would be one year, but may be up to two years. In the event the study is independently funded through a traditional research project grant (R01) or a FIRST (R29) award prior to the end of the award period, the support of the pilot study from the Developmental Fund must be terminated, and unexpended funds must be returned to the Developmental Fund. Funds reserved for pilot projects may not be rebudgeted into other budget categories except in unusual circumstances and following approval from the Awarding Unit and the Scientific Coordinator. The HC CRC must maintain detailed records of disbursements and expenditures of the Developmental Fund. Potential awardees and specific research projects to be pursued need not be identified in the application. However, the application should include a one page description of the kind of project that might be funded under this mechanism and how it interdigitates with other CRC projects. Approval of the developmental funds portion of the application does not in any way commit the program directors to the execution of the sample project. It is anticipated that prior to the HC CRC Program Director proposing pilot studies to the NIAID Scientific Coordinator, these studies and their budgets will be reviewed and recommended by a local review committee. The application must provide a description of the review process and selection criterion for proposed projects. Examples of criteria are scientific merit of the proposal, medical relevance and need for data to advance the research objectives of the HC CRC. It is recommended that no one applying for a development pilot project be on the review committee. Studies involving Human Subjects will require prior approval by the Institutional Review Board like all other NIH supported projects. The $30,000 annual direct costs should be entered in the OTHER category in the Consolidated Budget (see pages 12 and 19 in the accompanying brochure). Terms and Conditions of Award The following terms and conditions will be incorporated into the award notice. These special Terms of Award are in addition to, and not in lieu of, otherwise applicable OMB administrative guidelines, HHS Grant Administration Regulations at 45 CFR Parts 74 and 92, and other HHS, PHS, and NIH Grant Administration policy statements. The administrative and funding instrument used for this program is the agreement (U19), an "assistance" mechanism (rather than an "acquisition" mechanism), in which substantial NIH scientific and/or programmatic involvement with the awardee is anticipated during the performance of the activity. Under the agreement, the NIH's purpose is to support and/or stimulate the recipient's activity by involvement in and otherwise working jointly with the award recipient in a partner role, but it is not to assume direction, prime responsibility, or a dominant role in the activity. Awards will be made to an institution on behalf of a Program Director who will be responsible for the coordination of HC CRC scientific and administrative activities. Support of all HC CRC activities will be coordinated through a Central Operations Office located within the applicant organization. 1. Awardee Rights and Responsibilities Awardees will have primary responsibility for defining the details for the project within the guidelines of the RFA and for performing the scientific activity, and agree to accept close coordination, cooperation, and participation of NIAID staff in those aspects of scientific and technical management of the project as stated below under NIAID Staff Responsibilities. Specifically, awardees have primary responsibilities as described below. Under the Cooperative Agreement, a partnership relationship exists between the recipient of the award and NIAID in which successful applicants are responsive to the guidelines and conditions set forth in the RFA. At the same time, investigators are expected to define research objectives and approaches in accord with their own interests and perceptions of novel and exploitable approaches to the research which ultimately is likely to result in improved prevention and control of hepatitis C. It is the primary responsibility of the HC CRC Program Director to clearly state the objectives and approaches of the research, to plan and conduct the research stipulated in the application, and to ensure that the results obtained are analyzed and published in a timely manner. The HC CRC Program Director also will propose pilot studies to the NIAID Scientific Coordinator after review of these studies and their budgets by a local review committee. NIAID may periodically review and generate internal reports from data and progress reports developed under this agreement. The data obtained will, however, be the property of the awardee. 2. NIAID Staff Responsibilities The NIAID will have substantial scientific/programmatic involvement during the conduct of this activity, through technical assistance, advice and coordination above and beyond normal program stewardship for grants, as described below. The NIAID will work closely with the Program Directors and shall be represented by the Scientific Coordinator (Program Officer). The Scientific Coordinator will be the Hepatitis Program Officer in the Enteric Diseases Branch of NIAID. During the award period, the NIAID Scientific Coordinator may provide appropriate assistance, advice, and guidance in: o overall design of studies, e.g., prospective or intervention, especially those undertaken jointly by the HC CRCs; o linkage to special populations and vaccine production facilities funded through NIAID contracts, NIAID's data collection and analysis contracts, and DMID staff capabilities with respect to IND filing; o coordination and facilitation of information, technology, reagent and pedigree specimen exchange between HC CRCs themselves and with other grantees; o assistance in review and selection of developmental fund awardees; and o technical and administrative activities of HC CRCs. However, it is again emphasized that the role of NIAID will be TO FACILITATE AND NOT TO DIRECT THE ACTIVITIES of the HC CRCs. It is anticipated that decisions in all activities outlined within this RFA will be reached by consensus of the investigators and that the NIAID Scientific Coordinator will be given the opportunity to offer input to this process. In the event that research supported by the Cooperative Agreement results in development of a therapeutic or other medical intervention, NIAID will retain the option to cross-file or independently file an application for investigational clinical trial (i.e., an Investigational New Drug Application [INDA]) to the United States Food and Drug Administration. To facilitate this, reports of data generated by the HC CRC or any of its members which are required for inclusion in INDs and Clinical Brochures and for cross-filing purposes will be submitted by the Program Director to the Scientific Coordinator upon request. Such reports will be in final draft form and include background information, methods, results, and conclusion. They will be subject to approval and revision by NIAID and may be augmented with test results from other Government sponsored projects prior to submission to the appropriate regulatory agency. 3. Collaborative Responsibilities The HC CRC Program Directors and NIAID Scientific Coordinator will form a Joint Steering Committee which will meet at the NIH in Bethesda, Maryland (or at a site designated by NIAID) twice a year. Its functions include, but are not limited to: tracking and reviewing activities/progress over the six months between meetings, planning for the next six months and beyond, maintaining focus, and developing collaborative efforts among HC CRCs. The Program Directors and Scientific Coordinator will have voting rights. Issues for discussion and agendas will be a collaborative responsibility. The first steering committee meeting will occur shortly Post Award. Twice during the project period and in conjunction with the semi-annual Steering Committee meeting, workshops for the Program Directors and Project Leaders will be convened to share hepatitis C research advances, to discuss research needs and opportunities, and to develop collaborations. It is likely that these workshops will be convened in Year 1 and Year 3 of the project period at the NIH in Bethesda, Maryland (or at a site designated by NIAID). 4. Arbitration Any disagreement that may arise on scientific/programmatic matters (within the scope of the award) between award recipients and the NIAID may be brought to arbitration. An arbitration panel will be composed of three members -- one selected by the Program Director, a second member selected by the NIAID, and the third member selected by the two prior members. This special arbitration procedure in no way affects the awardee's right to appeal an adverse action that is otherwise appealable in accordance with PHS regulations at 42 CFR part 50, subpart D, and HHS regulation at 45 CFR part 16. STUDY POPULATIONS A strong emphasis is placed on studying hepatitis C in racial/ethnic populations that are disproportionately affected. These populations include African-Americans and Hispanics. Subjects may be recruited or specimens obtained from domestic sites or through collaborations with foreign institutions if the collaboration is beneficial to the foreign country and offers the potential for collection of hepatitis C data that are pertinent to U.S. populations and could not be generated as effectively in the United States. INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and members of minority groups and their sub-populations must be included in all NIH supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification is provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This new policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43) and supersedes and strengthens the previous policies (Concerning the Inclusion of Women in Study Populations, and Concerning the Inclusion of Minorities in Study Populations), which have been in effect since 1990. The new policy contains some provisions that are substantially different from the 1990 policies. All investigators proposing research involving human subjects should read the "NIH Guidelines For Inclusion of Women and Minorities as Subjects in Clinical Research," which have been published in the Federal Register of March 28, 1994 (FR 59 14508-14513) and printed in the NIH Guide for Grants and Contracts, Volume 23, Number 11, March 18, 1994. Investigators also may obtain copies of the policy from Dr. Johnson at the address listed under INQUIRIES. Dr. Johnson may also provide additional relevant information concerning the policy. LETTER OF INTENT Prospective applicants are asked to submit, by March 1, 1995, a letter of intent that includes a descriptive title of the overall proposed research, the name, address, and telephone number of the Program Director, a list of the key investigators and their institution(s), and the number and title of this RFA. Although the letter of intent is not required, is not binding, does not commit the sender to submit an application, and does not enter into the review of subsequent applications, the information that it contains allows NIAID staff to estimate the potential review workload and to avoid conflict of interest in the review. The letter of intent is to be sent to Dr. Olivia Preble at the address listed under INQUIRIES. APPLICATION PROCEDURES It is highly recommended that potential applicants contract Dr. Leslye Johnson in the early stages of application preparation. Before preparing an application, the applicant should carefully read the information brochure, "NIAID APPLICATION GUIDELINES FOR MULTIPROJECT RESEARCH AWARDS," available from the contacts listed under INQUIRIES. Instructions for formatting the application as outlined in the brochure should be followed carefully. Failure to follow the instructions may result in unnecessary delays in the review process. Applications are to be submitted on the standard research grant application form PHS 398 (rev. 9/91). These application forms may be obtained from the institution's office of sponsored research or its equivalent and from the Office of Grants Information, Division of Research Grants, National Institutes of Health, 5333 Westbard Avenue, Room 449, Bethesda, MD 20892, telephone (301) 710-0267. The RFA label available in the PHS 398 (rev. 9/91) application form must be affixed to the bottom of the face page of the application. Failure to use this label could result in delayed processing of the application such that it may not reach the review committee in time for review. In addition, the RFA title and number must be typed on line 2a of the face page of the application form and the YES box must be marked. Submit a signed, typewritten original of the application, including the checklist, and three signed, exact, single-sided photocopies, in one package, to: Division of Research Grants National Institutes of Health 6701 Rockledge Drive - MSC 7710 Bethesda, MD 20892-7710 Bethesda, MD 20817 (express mail) At the time of submission, two additional exact copies of the grant application and all five sets of appendix material must also be sent to: Dr. Olivia Preble Division of Extramural Activities National Institute of Allergy and Infectious Diseases Solar Building, Room 4C-20 MSC 7610 6003 Executive Boulevard Bethesda, MD 20892-7610 Rockville, MD 20852 (express mail) Applications must be received by July 18, 1995. All components, subparts and sections of the application must be collated into the application, and the packages sent to the DRG and to the NIAID must each be complete in themselves. Applications that do not conform to the instructions contained in PHS 398 (rev. 9/91) application kit will be judged nonresponsive and will be returned to the applicant. Current NIH policy permits a component research project of a multiproject grant application to be concurrently submitted as a traditional individual research project (R01) application. If, following review, both the multiproject application and the R01 application are found to be in the fundable range, the investigator must relinquish the R01 and will not have the option to withdraw from the multiproject grant. This is an NIH policy intended to preserve the scientific integrity of a multiproject grant, which may be seriously compromised if a strong component project(s) is removed from the program. Investigators wishing to participate in a multiproject grant must be aware of this policy before making a commitment to the Program Director and awarding institution. REVIEW CONSIDERATIONS Review Method Upon receipt, applications will be reviewed for completeness by the Division of Research Grants (DRG) for completeness and for responsiveness by NIAID staff. Incomplete and non-responsive applications will be returned to the applicant without further consideration or review. Those applications that are complete and responsive may be subjected to a triage by a peer review group to determine their scientific merit relative to other applications received in response to this RFA. The NIAID will remove from competition those applications judged to be non-competitive for award and will notify the Program Directors and institutional business officials. Those applications judged by the reviewers to be competitive for award will be further reviewed for scientific and technical merit by a review committee convened by the Division of Extramural Activities, NIAID. The second level of review will be provided by the National Advisory Allergy and Infectious Diseases Council. Review Criteria The standard review criteria are stated in the NIAID GUIDELINES FOR MULTIPROJECT RESEARCH AWARDS, which is available from the program staff listed under INQUIRIES. In addition, the following criteria will apply: o the scientific and technical significance, merit, and originality of the research projects and anticipated contributions to the understanding of HCV's immunology and disease; o the scientific expertise and experience of the Program Director, the Project Leaders and key project and core personnel; o documentation of a strong clinical capability, adequate and appropriate patient populations, disease prevalence, and historical success of recruitment and retention of subjects; o documentation of the sponsoring institution's commitment to the program and willingness to accept the participation and assistance of NIAID staff; o adequacy of proposed plan for coordination and communication within the applicant HC CRC and with NIAID and other HC CRCs; and o adequacy of proposed plan for selection of pilot studies. AWARD CRITERIA Funding decisions will be made on the basis of scientific and technical merit as determined by peer review, program balance, and availability of funds. INQUIRIES Written and telephone inquiries concerning this RFA are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic issues to: Dr. Leslye Johnson Division of Microbiology and Infectious Diseases National Institute of Allergy and Infectious Diseases Solar Building, Room 3A-22 MSC 7630 6003 Executive Boulevard Bethesda, MD 20892-7630 Telephone: (301) 496-7051 Email: lj7m@nih.gov Direct inquiries regarding review issues, address the letter of intent to, and mail two copies of the application and all five sets of appendices to: Dr. Olivia Preble Division of Extramural Activities National Institute of Allergy and Infectious Diseases Solar Building, Room 4C-20 MSC 7610 6003 Executive Boulevard Bethesda, MD 20892-7610 Rockville, MD 20852 Telephone: (301) 496-8208 Email: op2t@nih.gov Direct inquiries regarding fiscal matters to: Linda M. Shaw Division of Extramural Activities National Institute of Allergy and Infectious Diseases Solar Building, Room 4B-33 MSC 7610 6003 Executive Boulevard Bethesda, MD 20892-7610 Rockville, MD 20852 Telephone: (301) 496-7075 Email: lsl5k@nih.gov Schedule Letter of Intent Receipt Date: April 7, 1995 Application Receipt Date: July 18, 1995 Scientific Review Date: November 1995 Advisory Council Date: January 1996 Earliest Award Date: May 1, 1996 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.855 Immunology, Allergic and Immunological Diseases Research and 93.856 Microbiology and Infectious Diseases Research. Grants are awarded under the authority of the Public Health Service Act, Section 301 (42 USC 241) and administered under PHS grants policies and Federal Regulations, most specifically at 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of the Executive Order 12372 or Health Systems Agency review. The PHS strongly encourages all grant recipients to provide a smoke- free workplace and promote the non-use of all tobacco products. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people. .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |